SEC Form SC 13G/A filed by Certara Inc. (Amendment)

$CERT
Computer Software: Prepackaged Software
Technology
Get the next $CERT alert in real time by email
SC 13G/A 1 tm226510d1_sc13ga.htm SC 13G/A

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

 

Certara, Inc.

(Name of Issuer)

 

Common Stock, par value $0.01 per share

(Titles of Class of Securities)

 

15687V109

(CUSIP Number)

 

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

 

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨ Rule 13d-1(b)

 

¨ Rule 13d-1(c)

 

x Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out of a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

Schedule 13G

 

CUSIP No. 15687V109 Page 2 of 11

 

1  

NAME OF REPORTING PERSON

 

EQT Avatar Parent L.P.

2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨      (b) ¨

 

3  

SEC USE ONLY

 

4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

5  

SOLE VOTING POWER

 

37,458,939

6  

SHARED VOTING POWER

 

0

7  

SOLE DISPOSITIVE POWER

 

37,458,939

8  

SHARED DISPOSITIVE POWER

 

0

9  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

37,458,939

10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  ¨

 

11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

23.5%

12  

TYPE OF REPORTING PERSON

 

PN

 

 

 

 

Schedule 13G

 

CUSIP No. 15687V109 Page 3 of 11

 

1  

NAME OF REPORTING PERSON

 

EQT Avatar Parent GP LLC

2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨      (b) ¨

 

3  

SEC USE ONLY

 

4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

5  

SOLE VOTING POWER

 

37,458,939

6  

SHARED VOTING POWER

 

0

7  

SOLE DISPOSITIVE POWER

 

37,458,939

8  

SHARED DISPOSITIVE POWER

 

0

9  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

37,458,939

10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  

 

11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

23.5%

12  

TYPE OF REPORTING PERSON

 

OO

 

 

 

 

Schedule 13G

 

CUSIP No. 15687V109 Page 4 of 11

 

1  

NAME OF REPORTING PERSON

 

EQT Fund Management S.à r.l.

2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨      (b) ¨

 

3  

SEC USE ONLY

 

4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Luxembourg

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

5  

SOLE VOTING POWER

 

37,458,939

6  

SHARED VOTING POWER

 

0

7  

SOLE DISPOSITIVE POWER

 

37,458,939

8  

SHARED DISPOSITIVE POWER

 

0

9  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

37,458,939

10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  

 

11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

23.5%

12  

TYPE OF REPORTING PERSON

 

OO

 

 

 

 

Schedule 13G

 

CUSIP No. 15687V109 Page 5 of 11

 

Item 1(a). Name of Issuer:

 

Certara, Inc.

 

Item 1(b). Address of Issuer’s Principal Executive Offices:

 

100 Overlook Center, Suite 101

Princeton, New Jersey 08540

 

Item 2(a). Name of Person Filing:

 

This Amendment Number 1 to the Statement on Schedule 13G filed on February 16, 2021 (“Amendment No. 1”) is being filed jointly by EQT Avatar Parent L.P. (the “EQT Investor”), EQT Avatar Parent GP LLC (“Avatar Parent GP”), and EQT Fund Management S.à r.l. (“EFMS”) (each a “Reporting Person” and, together, the “Reporting Persons”), pursuant to an agreement of joint filing, a copy of which is attached hereto as Exhibit 1.

 

Avatar Parent GP is the general partner of the EQT Investor. Several investment vehicles collectively make up the fund known as “EQT VII.” EQT VII owns 100% of the membership interests in Avatar Parent GP. EFMS has exclusive responsibility for the management and control of the business and affairs of investment vehicles which constitute the majority of the total commitments to EQT VII. As such, EFMS has the power to control Avatar Parent GP's voting and investment decisions and may be deemed to have beneficial ownership of the securities held by the EQT Investor. EFMS is managed by a five-member board of directors.

 

Each of Avatar Parent GP and EFMS may be deemed to beneficially own the shares of Common Stock (as defined below) beneficially owned by the EQT Investor, but neither the filing of this Amendment No. 1 nor any of its contents shall be deemed to constitute an admission that any Reporting Person (other than the EQT Investor) is the beneficial owner of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Act”), or for any other purpose and each of Avatar Parent GP and EFMS expressly disclaim beneficial ownership of such shares. The filing of this statement should not be construed to be an admission that any of the Reporting Persons are members of a “group” for the purposes of Sections 13(d) and 13(g) of the Act.

 

Item 2(b). Address of Principal Business Office or, if none, Residence:

 

The address of the principal business office of the EQT Investor and Avatar Parent GP is:

 

c/o EQT Partners

1114 Avenue of the Americas, 45th Floor

New York, NY 10036

 

The address of the principal business office of EFMS is:

 

26A, Boulevard Royal,

L-2449 Luxembourg, Grand Duchy of Luxembourg

 

Item 2(c). Citizenship:

 

See response to Item 4 of each of the cover pages and Item 2(a) above.

 

Item 2(d). Titles of Classes of Securities:

 

Common stock, par value $0.01 per share (“Common Stock”).

  

Item 2(e). CUSIP Number:

 

15687V109

  

 

 

 

Schedule 13G

 

CUSIP No. 15687V109 Page 6 of 11

 

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a(n):

 

Not applicable.

 

Item 4. Ownership

 

  (a) Amount Beneficially Owned:

 

The information contained in rows 5, 6, 7, 8, 9, 10, and 11 on each of the cover pages of this Amendment No. 1 and the information set forth or incorporated in Item 2(a) is incorporated by reference in its entirety into this Item 4.

 

The Reporting Persons may be deemed to beneficially own an aggregate of 37,458,939 shares of the Issuer’s Common Stock, which constitutes approximately 23.5% of the total outstanding Common Stock of the Issuer, based upon an aggregate of 159,658,948 shares of Common Stock outstanding as of December 31, 2021.

 

  (b) Percent of Class:

 

See responses to Item 11 on each cover page and Items 2(a) and 4(a) above.

 

  (c) Number of shares as to which such person has:

 

  (i) Sole power to vote or to direct the vote:

 

See responses to Item 5 on each cover page and Items 2(a) and 4(a) above.

 

  (ii) Shared power to vote or to direct the vote:

 

See responses to Item 6 on each cover page and Items 2(a) and 4(a) above.

 

  (iii) Sole power to dispose or to direct the disposition of:

 

See responses to Item 7 on each cover page and Items 2(a) and 4(a) above.

 

  (iv) Shared power to dispose or to direct the disposition of:

 

See responses to Item 8 on each cover page and Items 2(a) and 4(a) above.

 

Item 5. Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

The several investment vehicles that collectively constitute the EQT VII fund may be deemed to have the indirect right to receive or the indirect power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock held by the EQT Investor by virtue of their ownership of Avatar Parent GP’s membership interests. Of these vehicles, each of EQT VII (No. 1) Limited Partnership and EQT VII (No. 2) Limited Partnership may be deemed to have the indirect right to receive or the indirect power to direct the receipt of dividends from, or the proceeds from the sale of, 5.0% or more of the Issuer’s outstanding Common Stock.

 

 

 

 

Schedule 13G

 

CUSIP No. 15687V109 Page 7 of 11

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not applicable.

 

Item 10. Certification.

 

Not applicable.

 

 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 14, 2022

 

  EQT Avatar Parent L.P.
  By: EQT Avatar Parent GP LLC, its general partner
   
  By: /s/ Marie Louise van Dam
    Name: Marie Louise van Dam
    Title:   President
     
  By: /s/ Adam Larsson
    Name: Adam Larsson
    Title:   Vice President
   
  EQT Avatar Parent GP LLC
   
  By: /s/ Marie Louise van Dam
    Name: Marie Louise van Dam
    Title:   President
     
  By: /s/ Adam Larsson
    Name: Adam Larsson
    Title:   Vice President
   
  EQT Fund Management S.à r.l.
   
  By: /s/ Peter Veldman
    Name: Peter Veldman
    Title:   Manager
   
  By:  /s/ Nicholas Curwen
    Name: Nicholas Curwen
    Title:   Manager

 

 

 

 

Exhibit Index

 

Exhibit 1   Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act (incorporated by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons on February 16, 2021).

 

 

Get the next $CERT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CERT

DatePrice TargetRatingAnalyst
2/27/2025$16.00Buy
TD Cowen
9/27/2024$16.00Neutral → Buy
UBS
4/10/2024$23.00Sector Weight → Overweight
KeyBanc Capital Markets
4/4/2024Mkt Perform
JMP Securities
2/26/2024$19.00Market Perform
Leerink Partners
12/7/2023$17.00Neutral
UBS
12/5/2023Sector Weight
KeyBanc Capital Markets
8/22/2023$24.50 → $17.00Buy → Hold
Jefferies
More analyst ratings

$CERT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

    RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with t

    $CERT
    Computer Software: Prepackaged Software
    Technology
  • Certara Reports Fourth Quarter 2024 Financial Results

    RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024. Fourth Quarter Highlights: Revenue was $100.4 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 14%. Software revenue was $42.3 million, compared to $33.6 million in the fourth quarter of 2023, representing growth of 26%.Services revenue was $58.1 million, compared to $54.4 million in the fourth quarter of 2023, representing growth of 7%. Net income was $6.6 million, compared to a net loss of $12.5 million in the fourth quarter of 2023.Adjuste

    $CERT
    Computer Software: Prepackaged Software
    Technology
  • Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences

    RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market close on Wednesday, February 26th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara also announced that company management will participate in the following investor conferences: Leerink Partners Global Healthcare ConferenceDate and Time: Tuesday

    $CERT
    Computer Software: Prepackaged Software
    Technology

$CERT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CERT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CERT
SEC Filings

See more

$CERT
Leadership Updates

Live Leadership Updates

See more
  • Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

    RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with t

    $CERT
    Computer Software: Prepackaged Software
    Technology
  • Certara Appoints John Reynders as New Independent Board Member

    RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. "We are excited to welcome an accomplished pharmaceutical industry leader with a track record of success to Certara's Board," said William F. Feehery, PhD, CEO of Certara. "John's expertise in artificial intelligence, data science, and life science will provide immense value. We will draw on that expertise as we continue to develop and integrate transformational software and services that accelerate new medicines and increase the productivity of pharma R&

    $CERT
    Computer Software: Prepackaged Software
    Technology
  • MaxCyte Appoints Cynthia Collins to its Board of Directors

    ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe

    $CERT
    $MXCT
    $PSTX
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$CERT
Financials

Live finance-specific insights

See more
  • Certara Reports Fourth Quarter 2024 Financial Results

    RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024. Fourth Quarter Highlights: Revenue was $100.4 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 14%. Software revenue was $42.3 million, compared to $33.6 million in the fourth quarter of 2023, representing growth of 26%.Services revenue was $58.1 million, compared to $54.4 million in the fourth quarter of 2023, representing growth of 7%. Net income was $6.6 million, compared to a net loss of $12.5 million in the fourth quarter of 2023.Adjuste

    $CERT
    Computer Software: Prepackaged Software
    Technology
  • Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences

    RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market close on Wednesday, February 26th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara also announced that company management will participate in the following investor conferences: Leerink Partners Global Healthcare ConferenceDate and Time: Tuesday

    $CERT
    Computer Software: Prepackaged Software
    Technology
  • Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

    Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 millionConfirms Adjusted EBITDA within Guidance Range of $120 million to $124 million RADNOR, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced revenue and bookings for the fourth quarter and full year of fiscal year 2024 based on a preliminary review of fourth quarter results. Preliminary financials for the fourth quarter of 2024 are expected to be as follows: Revenue of $99.7 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 13%. Software revenue of $41.6 million, compared to $33.6 million in th

    $CERT
    Computer Software: Prepackaged Software
    Technology

$CERT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more